- Price
- $80.75
- Day
- -0.98%
- Mkt Cap
- $2.79B
- 52W Range
- $60.11 – $156.00
- Volume
- 1.29M
- Beta
- 1.88
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript
Read full article
TransMedics Group NASDAQ: TMDX reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure.
Read full article
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026.
Read full article
TransMedics (TMDX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.92 per share a year ago.
Read full article
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].
Read full article
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMe
Read full article
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 29, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics.
Read full article
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026.
Read full article
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Read full article
Bessemer Group Inc. grew its stake in shares of TransMedics Group, Inc. (NASDAQ: TMDX) by 38.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,821 shares of the company's stock after purchasing an additional 12,812 shares during the period. Bessemer Group Inc. owned
Read full article